Cart
sales@molnova.com
SU5208
CAS No. 62540-08-3
SU5208( 3-[(Thien-2-yl)methylene]-2-indolinone )
Catalog No. M22956 CAS No. 62540-08-3
SU5208 is a compound with bioactivity.SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 87 | In Stock |
|
| 5MG | 95 | In Stock |
|
| 10MG | 151 | In Stock |
|
| 25MG | 238 | In Stock |
|
| 50MG | 321 | In Stock |
|
| 100MG | 449 | In Stock |
|
| 200MG | 603 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSU5208
-
NoteResearch use only, not for human use.
-
Brief DescriptionSU5208 is a compound with bioactivity.SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2).
-
DescriptionSU5208 is a compound with bioactivity.SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2).
-
In Vitro——
-
In Vivo——
-
Synonyms3-[(Thien-2-yl)methylene]-2-indolinone
-
PathwayAngiogenesis
-
TargetVEGFR
-
RecptorVEGFR2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number62540-08-3
-
Formula Weight227.28
-
Molecular FormulaC13H9NOS
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (439.99 mM)
-
SMILESO=C1NC2=C(C=CC=C2)/C1=C/C3=CC=CS3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Camila Mu?oz, et al. Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations. J Mol Graph Model. 2012 Feb;32:39-48.
molnova catalog
related products
-
PAN-90806
PAN-90806 (CP-547632, CP547632) is a highly potent, ATP-competitive, orally active VEGFR-2 inhibitor that blocks VEGFR-2 kinase autophosphorylation (IC50=11 nM) and VEGF-induced VEGFR-2 phosphorylation (IC50=5 nM).
-
Linifanib
A potent multi-RTKs inhibitor of members of VEGFR and PDGFR families.
-
Vatalanib
A potent, orally available class III receptor tyrosine kinases inhibitor with IC50 of <1 uM for VEGFR, Flt-1, KDR and PDGFRβ.
